Navigation Links
Unigene to Present at the Oppenheimer 22nd Annual Healthcare Conference on December 13, 2011
Date:12/7/2011

BOONTON, N.J., Dec. 7, 2011 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced that Ashleigh Palmer, President and Chief Executive Officer, will be presenting a corporate overview at the 22nd Annual Oppenheimer Healthcare Conference being held in New York City.  Mr. Palmer's live presentation is scheduled to begin at 4:10 p.m. ET on Tuesday, December 13, 2011.

A live webcast of the presentation will be available by logging on to the Investors and Media section under the Events tab of the Unigene web site, http://www.unigene.com. Participants should allow approximately five to 10 minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the Company's web site for 30 days.

About Unigene Laboratories, Inc.:
Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Investor Contact:
Unigene Laboratories, Inc.
Jenene Thomas
VP, Investor Relations and Business Administration
973-265-1107
jthomas@unigene.com

Media Contact:'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Unigene Announces Positive Top-Line Results of Phase 2 Oral PTH Study for the Treatment of Osteoporosis in Postmenopausal Women
2. Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
3. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
4. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
5. Uroplasty to Present at the Oppenheimer 22nd Annual Healthcare Conference
6. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
7. Agendia to Present Five Abstracts at 2011 San Antonio Breast Cancer Symposium
8. diaDexus, Inc. to Present at the Canaccord Genuity Healthcare Conference
9. Senesco Technologies, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
10. MiMedx Group, Inc. to Present at the 6th Annual Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference
11. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014 The global market for biotechnology ... according to a new study by Grand View Research, ... for effective vaccines and drugs in an attempt to ... is expected to drive market demand over the next ... productivity via the use of genetically engineered seeds is ...
(Date:7/26/2014)... 2014 Canada Endoscopy Visualization Systems ... on the Canada Endoscopy Visualization Systems market. The ... volume (in units) and average prices (in US ... Systems, Mid-Range Endoscopy Visualization Systems and Low-End Endoscopy ... http://www.marketresearchreports.biz/analysis/213254 . , The report also provides company ...
(Date:7/25/2014)... July 25, 2014 Research and ... "Global Metabolomics Market 2014-2018" report to their ... Metabolomics or Metabonomics is the scientific ... become a new experimental technique that is being ... sciences. Metabolites are small molecules that are present ...
(Date:7/25/2014)... 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... development and commercialization of a once-daily, oral therapy for ... announced financial results for the period ended June 30, ... , Reported cash and cash equivalents totaling $37.4 million ... 31, 2013.  , Reported a net loss of ...
Breaking Biology Technology:Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6
... May 11 Amicus Therapeutics (Nasdaq: ... Matthew R. Patterson, will be presenting at the upcoming Bank ... Mr. Patterson,s presentation is scheduled to begin on Wednesday, ... live webcast of the presentation by logging on to the ...
... NEW YORK, May 11 /PRNewswire-Asia-FirstCall/ -- American Oriental,Bioengineering, Inc. ... to,improving health through the development, manufacture and commercialization of,a ... products in China,today announced financial results for the first ... Financial Results , Revenue ...
... May 9 Oxford Biomedica,s,second attempt to dismiss Bavarian ... Instead of denying infringement, Oxford Biomedica,made yet another attempt ... TroVax(R) was still evaluated in clinical trials. The court ... based on the,substance of the patents. , ...
Cached Biology Technology:American Oriental Bioengineering Reports First Quarter 2009 Financial Results 2American Oriental Bioengineering Reports First Quarter 2009 Financial Results 3American Oriental Bioengineering Reports First Quarter 2009 Financial Results 4American Oriental Bioengineering Reports First Quarter 2009 Financial Results 5American Oriental Bioengineering Reports First Quarter 2009 Financial Results 6American Oriental Bioengineering Reports First Quarter 2009 Financial Results 7The Court Supports Bavarian Nordic's Decision to Start Patent Infringement Case Against Oxford BioMedica 2
(Date:7/27/2014)... revealed that nicotine and cotinine, a metabolite of nicotine, ... carcinogen in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone or NNK ... ultimately ends up in the tobacco smoke. Once inhaled, ... it is activated by a variety of enzymes called ... that nicotine can partially interfere with the activation of ...
(Date:7/27/2014)... like bacteria and fungi can evade treatment by acquiring ... drugs. These permanent mutations were once thought to be ... a new study has shown that microorganisms can use ... epimutations -- to gain the benefits of drug resistance ... discovered in a fungus called Mucor circinelloides, it is ...
(Date:7/27/2014)... from over 18,000 patients, scientists have identified more ... Parkinson,s disease, including six that had not been ... Genetics , was partially funded by the National ... working in NIH laboratories. , "Unraveling the genetic ... multiple mechanisms involved in this complex disease, and ...
Breaking Biology News(10 mins):Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3NIH scientists find 6 new genetic risk factors for Parkinson's 2
... Just as scientists finished sequencing the human genome, they ... DNA produces proteins to sustain life, they found microRNA. ... channel in biology, allowing scientists to more closely examine ... tick. "This is a pivotal mechanism for solving ...
... Ore Oregon Health & Science University researchers, along ... uncovering new information about the mind by studying the ... this research will one day provide new tools for ... treatments. The researchers, latest findings are published in the ...
... Universit de Montreal (UdeM) and the Montreal Neurological Institute ... support nerve cell (neuron) survival also play an active ... the eye. The findings, published this week in The ... streamlined therapies for a variety of acute and chronic ...
Cached Biology News:Meet DNA's personal assistants 2OHSU researchers study the idling brain 2Cell's split personality is a major discovery into neurological diseases 2
Edited by I.H. Pawlowitzki, J.H. Edwards and E.A. Thompson (1997) • This volume covers: Linkage in dominant recessive and oligogenic disease, Model free (non-parametric) methods, Tools for gene ...
... Cloning is the most ... cloning PCR products. TOPO ... Blunt TOPO vectors are ... with topoisomerase I. This ...
Applications: ISH...
... ZMD.420. Immunogen: Recombinant human ... Specific for the ~44 kDa ... Human (positive control: IFN-Gamma-stimmulated Human ... sequence homology reactivity with mouse ...
Biology Products: